Elevated elimination rates of quetiapine in adolescent patients with schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders in impulse control with current PTSD (ICD 10: F 43.1) or personality disorder (ICD 10: F 60.-): clinical trial for genotypying of two metabolizing enzymes (CYP2D6 und CYP3A5*3). (Erhöhte Eliminationsraten von Quetiapin bei jugendlichen Patienten mit Schizophrenie (ICD 10: F 20.-), bipolar affektiver Störung (ICD 10: F 31.-) bzw. Störung der Impulskontrolle bei vorliegender PTBS (ICD 10: F 43.1) oder Persönlichkeitsstörung (ICD 10: F 60.-): Klinische Studie zur Genotypisierung zweier metabolisierender Enzyme (CYP2D6 und CYP3A5*3).)

Trial Profile

Elevated elimination rates of quetiapine in adolescent patients with schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders in impulse control with current PTSD (ICD 10: F 43.1) or personality disorder (ICD 10: F 60.-): clinical trial for genotypying of two metabolizing enzymes (CYP2D6 und CYP3A5*3). (Erhöhte Eliminationsraten von Quetiapin bei jugendlichen Patienten mit Schizophrenie (ICD 10: F 20.-), bipolar affektiver Störung (ICD 10: F 31.-) bzw. Störung der Impulskontrolle bei vorliegender PTBS (ICD 10: F 43.1) oder Persönlichkeitsstörung (ICD 10: F 60.-): Klinische Studie zur Genotypisierung zweier metabolisierender Enzyme (CYP2D6 und CYP3A5*3).)

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2013

At a glance

  • Drugs Midazolam (Primary) ; Quetiapine (Primary)
  • Indications Bipolar disorders; Impulse control disorders; Personality disorders; Post-traumatic stress disorders; Schizophrenia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 14 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top